Scientists probe immune cell exhaustion in hepatitis b
NCT ID NCT03761875
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why NK cells stop working properly in HBV patients, which could help develop better treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal why the immune system fails to clear hepatitis B, pointing toward new treatment targets.
- What could go wrong
- This is an observational study with no treatment given, so it won't directly help patients. Results may not lead to therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2018
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for participation in this study: * Male or female, age ≥18 years * HBV infection or chronic HBV infection * Willing and able to provide written informed consent Healthy donors must meet all of the following inclusion criteria to be eligible for participation in this study: * Male or female, age between 18 and 50 years * Willing and able to provide written informed consent Exclusion Criteria: * Subjects who meet any of the following exclusion criteria are not to be enrolled in this study: * Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) * Chronic liver disease of a non-HBV etiology * Immune or cancerous disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hepatitis B virus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Limoges Hospital
Limoges, 87 042, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.